

**PRESS RELEASE**

**Ad hoc announcement pursuant to article 53 LR**

## **LEPU Medical Technology(Beijing) Announces Results for the Third Quarter of 2022**

Beijing, China, October 27, 2022- LEPU Medical Technology(Beijing) Co.,Ltd.(the “Company”) today announced its performance for the nine months ended September 30, 2022:

- For the third quarter of 2022, the operating revenue reached RMB 2428.2923 million, with an increase of 14.87% compared to the same period of last year ; after deducting the income of COVID-19 antigen rapid test kits, the routine business increased by 20.22%.
- For the third quarter of 2022, the net profits attributable to shareholders of the Company was RMB 542.0750 million with 177.49% compared to the same period of last year. The net profits attributable to shareholders of the Company after deducting non-recurring profit and loss was RMB 541.2646 with 47.32% compared to the same period of last year .
- During the first nine months of 2022, the operating revenue decreased by 10.11%, or RMB 872.8061 million, to RMB 7761.7992 million compared to the same period of last year. The decrease in operating revenue was mainly due to the high sales of COVID-19 antigen rapid test kits in 2021. The total operating revenue of COVID-19 antigen rapid test kits accounted for 7.5%, and the operating revenue of this business dropped 77% compared to the same period of last year. After deducting the revenue of COVID-19 antigen rapid test kits, the revenue of routine business increased by 18.45% compared to the same period of last year.
- During the first nine months of 2022, the Company realized a net profit of RMB 1836.0580 million with a decline of 8.79% over the same period of last year; The net profits attributable to shareholders of the Company was RMB 1810.1027

million with a decline of 5.78% over the same period of last year. The net profit attributable to shareholders of the Company after deducting non-recurring profit and loss was RMB 1804.7750 million with a decline of 13.44% over the same period of last year; the net profits attributable to shareholders of the Company decreased due to the significant decrease in antigen testing related business compared with the same period in 2021.

### Financial Results(unaudited)

	Three Months Ended September 30, 2022	% Change	Nine Months Ended September 30, 2022	% Change
Operating revenue(RMB)	2,428,292,257.91	14.87%	7,761,799,196.45	-10.11%
Net profit attributable to shareholders of the Company (RMB)	542,075,039.22	177.49%	1,810,102,684.93	-5.78%
Net profit attributable to shareholders of the Company after deducting non-recurring profit and loss (RMB)	541,264,649.98	47.32%	1,804,775,009.94	-13.44%
Net cash flows from operating activities (RMB)	643,377,663.85	236.06%	1,821,670,641.59	-21.66%
Basic earnings per share (RMB /share)	0.3041	178.98%	1.0158	-5.24%
Diluted earnings per share (RMB /share)	0.3017	176.77%	1.0051	-4.66%
Return on weighted average net assets	4.39%	2.72%	15.04%	-2.66%

## **Full third quarter report**

The full three-quarter results report as of and for the nine months ended September 30, 2022 is available on our website at <https://en.lepumedical.com/investors/>.

## **Contact information**

Ms. Weina Jiang

Phone: +86 010 80120622

E-mail: [zqb@lepumedical.com](mailto:zqb@lepumedical.com)

## **About LEPU**

LEPU Medical Technology(Beijing) Co.,Ltd was the total-solution provider in the PRC across the full life cycle of cardiovascular disease management, with products and services encompassing medical devices, pharmaceuticals, and medical care solutions Company is one of the earliest companies in the PRC to offer coronary interventional products and have consolidated our first-mover advantage through relentless innovation since our inception in 1999. Our key products, namely, coronary drug-eluting stent, coronary bioresorbable scaffold, coronary drug-coated balloon, congenital heart disease occluder and coronary cutting balloon. Our leading R&D expertise and capabilities have enabled us to develop and successfully commercialize a comprehensive portfolio of products. We focus our R&D efforts on unmet clinical needs. We have developed and commercialized the first fully biodegradable occluder in the world and many first Chinese brand products, such as coronary stent, cardiac pacemaker, bioresorbable scaffold and coronary cutting balloon. In addition, we are the first PRC company to apply AI technology to ECG devices. Furthermore, benefiting from our diverse technology platforms, we have developed over 80 product candidates for cardiovascular devices and peripheral artery devices across coronary

artery diseases, structural heart diseases, cardiac rhythm management, electrophysiology and other segments.

## **Disclaimers**

This announcement contains forward-looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified by the use of forward looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release.